Abstract: This article provides a systematic interpretation of the content related to pancreatic neuroendocrine neoplasms (pNENs) in the NCCN Clinical Practice Guidelines for Neuroendocrine (2025.V2). pNENs are highly heterogeneous, requiring multidisciplinary management. The guidelines reflect the concept of precision medicine, facilitating diagnosis and risk stratification through the integration of pathological grading, molecular characteristics, and functional imaging. In terms of treatment, an individualized approach is advocated: surgical decisions for localized disease should consider tumor size, grade, and patient condition; for advanced disease, systemic therapy selection depends on tumor biology and specific molecular targets. Additionally, the guidelines highlight genetic risk assessment and long-term follow-up, recommending germline testing for eligible patients and structured surveillance for over 10 years. Overall, these guidelines provide a systematic and evidence-based comprehensive framework for the clinical management of pNENs.

Key words: pancreatic neuroendocrine neoplasms, National Comprehensive Cancer Network, clinical practice guidelines, diagnosis and treatment standards